A Case of Therapy-Related Acute Monocytic Leukemia following Low-dose of Etoposide Treatment for Hemophagocytic Lymphohistiocytosis.
10.3343/kjlm.2007.27.4.244
- Author:
Young Ik SEO
1
;
Rojin PARK
;
Tae Youn CHOI
;
Jeung Won SHIN
;
Jong Ho WON
;
Hee Sook PARK
;
Nam Soo LEE
;
Duck CHO
Author Information
1. Department of Laboratory Medicine, Soonchunhyang University Hospital, Seoul, Korea.rpark@hosp.sch.ac.kr
- Publication Type:Case Report ; English Abstract
- Keywords:
Etoposide;
Hemophagocytic lymphohistiocytosis;
Therapy-related acute leukemia
- MeSH:
Bone Marrow/pathology;
Etoposide/administration & dosage/*adverse effects;
Female;
Humans;
Leukemia, Monocytic, Acute/*chemically induced/*diagnosis/therapy;
Lymphohistiocytosis, Hemophagocytic/complications/*drug therapy;
Middle Aged
- From:The Korean Journal of Laboratory Medicine
2007;27(4):244-247
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We report a case of therapy-related acute myeloid leukemia after low-dosed topoisomerase II inhibitor (etoposide) treatment for hemophagocytic lymphohistiocytosis (HLH). A 62-yr-old female patient had previously been treated with a HLH-94 protocol containing a low-dose of etoposide (total dose of 300 mg/m2). Thirty-one months later, the patient was admitted to the hematology department with general weakness and upper respiratory infection symptoms. Peripheral blood smear and bone marrow study revealed acute monocytic leukemia. There was no evidence of myelodysplastic syndrome, and a cytogenetic study showed no chromosomal abnormalities.
